Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05225493
Other study ID # MEC-2021-0277
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2020
Est. completion date May 2024

Study information

Verified date January 2022
Source Erasmus Medical Center
Contact Casper Rokx, MD PhD
Phone +31681336328
Email c.rokx@erasmusmc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Patients are frequently evaluated by physicians for medical work-up of HIV indicator conditions in hospital and in primary care at the general practitioner. Testing for HIV is indicated with HIV indicator disorder but often omitted in clinical work-up. Besides the fact that HIV testing is forgotten, there are other reasons such as an underestimation of the risk of HIV in the event of indicator disorders, stigma and difficulties in discussing the test with a patient. Also and more relevant for primary care than for the hospital, practical challenges can exist for a patient to go to a laboratory, or costs are a hurdle. This project focuses on improving HIV indicator condition driven testing in different settings of the HIV epidemic, initially in the Netherlands as low HIV prevalence setting followed by an assessment of its benefit in different international settings. A specific focus will also be on the Rotterdam area in the Netherlands which has a high prevalence of undiagnosed HIV in the Netherlands. The ultimate aim is to decrease the number of undiagnosed HIV in populations, improve the 90-90-90 HIV cascade of care goals particularly its first pillar, and to help supporting the UNAIDS goal to end HIV/AIDS


Recruitment information / eligibility

Status Recruiting
Enrollment 1500
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of an HIV indicator conditions. Exclusion Criteria: - Below 18 years of age - Recent HIV test (< 12 months, except for mononucleosis-like disease and STDs)

Study Design


Related Conditions & MeSH terms

  • Acquired Immunodeficiency Syndrome
  • Candida Infection
  • Candidiasis
  • Cervical Intraepithelial Neoplasia
  • Communicable Diseases
  • Dermatitis
  • Dermatitis, Seborrheic
  • Diarrhea
  • Diarrhea Chronic
  • Disease
  • Herpes Zoster
  • HIV Infections
  • Immunologic Deficiency Syndromes
  • Infections
  • Infectious Mononucleosis
  • Leukopenia
  • Lymphadenopathy
  • Pneumonia
  • Primary Health Care
  • Psoriasis
  • Sexually Transmitted Diseases
  • Sexually Transmitted Diseases, Viral
  • Thrombocytopenia
  • Uterine Cervical Dysplasia
  • Virus Diseases
  • Weight Loss

Intervention

Behavioral:
Peer to peer feedback
HIV experts contact non-HIV specialised treating physicians on individual patient care to recommend HIV testing
Diagnostic Test:
HIV rapid test
Free HIV rapid tests are provided to non-HIV specialised treating physicians to use in individual patient care in patients at risk of HIV

Locations

Country Name City State
Netherlands Carlijn CCE Jordans Rotterdam South-Holland

Sponsors (12)

Lead Sponsor Collaborator
Erasmus Medical Center AwareHIV Project Group, Huisartsen Groep Rotterdam, Huisartspraktijk Capelle ad IJssel, Huisartspraktijk Gezondheidscentrum Mathenesserlaan, Huisartspraktijk Handellaan, Huisartspraktijk Leerdam, Leiden University Medical Center, Maasstadziekenhuis, Medical Center Haaglanden, Rijnstate Hospital, TU Delft department of Artificial Intelligence and MyTomorrows

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other The number of HIV tests in relation to the total number of HIV tests done by gender, ethnical background, age, previous HIV test and HIV indicator conditions of the patient, primary care setting and hospital setting. 3 year
Other Center for Disease Control and Prevention (CDC) HIV classification of the patients with an HIV positive test. 3 year
Primary The number of adequately performed HIV tests of identified HIV indicator conditions in relation to the total number of identified HIV indicator conditions by physicians in hospital settings during the project. 3 year
Primary The number of adequately performed HIV tests of identified HIV indicator conditions in relation to the total number of identified HIV indicator conditions by general practitioners in primary care during the project. 3 year
Secondary The number of positive HIV tests in relation to the total number of HIV tests for identified HIV indicator conditions. 3 year
Secondary The percentage of adequately HIV tested patients per HIV indicator condition and per medical specialism. 31 year
Secondary The prevalence of HIV indicator conditions in primary care and hospitals. 3 year
Secondary The incidence of HIV indicator conditions in primary care and hospitals. 3 year
Secondary A sensitive and specific supervised artificial Intelligence tool that recognizes risk factors for HIV and HIV indicator conditions through natural language processing (NLP) and supports the hospital and primary care in proactive HIV testing policies. 3 year
Secondary Acceptance of HIV testing in by patients, medical specialist and in primary care. Assessed by questionnaire 3 year
Secondary The costs of pro-active HIV indicator case finding and relation to the savings and QALY's gained Costs of the program in relation to the savings in costs and QALY's lost as a consequence of earlier HIV diagnosis with subsequent prevented HIV transmission, AIDS comorbidity and hospital admissions. 3 year
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2